- Corcept Therapeutics (CORT +3.8%) is up on 66% higher volume in reaction to its win in a challenge to a key patent protecting Cushing's disease med Korlym (mifepristone) which accounts for all of the company's sales.
- The USPTO's Patent Trial and Appeal Board ruled that would-be competitor Neptune Generics failed to prove that the patent, U.S. No. 8,921,348 for optimizing levels of mifepristone, does not represent a new invention.
- Teva Pharmaceutical Industries (TEVA +1.5%) is challenging another Korlym patent ('214) with a PTAB decision expected in November.